Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SepternaSEPN -1.77%12 PB Ratio is 4.61 as of Aug. 08, 2026, which is 84% above its 10-year median of 2.50. GuruFocus rates SEPN with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, Septerna ranks worse than 67.35% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-08), Septerna's share price is $38.83. Septerna's Book Value per Share for the quarter that ended in Mar. 2026 was $8.43. Hence, Septerna's PB Ratio of today is 4.61.
Warning Sign:
Septerna Inc stock PB Ratio (=4.69) is close to 2-year high of 4.69.
The historical rank and industry rank for Septerna's PB Ratio or its related term are showing as below:
SEPN'
s PB Ratio Range Over the Past 10 Years
Min: 0.61 Med: 2.5 Max: 4.82
Current: 4.61
During the past 4 years, Septerna's highest PB Ratio was 4.82. The lowest was 0.61. And the median was 2.50.
SEPN's PB Ratio is ranked worse than 67.35% of 1228
companies
in the Biotechnology industry
Industry Median: 2.905
vs SEPN: 4.61
During the past 12 months, Septerna's average Book Value Per Share Growth Rate was -6.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Septerna PB Ratio Related Terms
Septerna PB Ratio Historical Data
* Premium members only.
The historical data trend for Septerna's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Septerna's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Septerna PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Septerna's PB Ratio distribution charts can be found below:
* The bar in red indicates where Septerna's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Septerna's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Septerna (SEPN) has a PB Ratio of 4.61 as of Aug. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Septerna and its competitors. This is 84% above median its historical median of 2.50. Over the past decade, Septerna's PB Ratio has ranged from 0.61 to 4.82. According to the industry distribution chart, Septerna ranks #827 out of 1228 companies in the Biotechnology industry, placing it in the top 67.3%.
Is Septerna's PB Ratio too high?
Septerna's current PB Ratio of 4.61 is 84% above median its 10-year median of 2.50. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 4.82. The Biotechnology industry median PB Ratio is 2.91. Septerna's value of 4.61 is 58.7% above this industry median. Based on the distribution chart, Septerna ranks #827 out of 1228 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Septerna has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Septerna's PB Ratio compare to NTLA and AVBP?
According to the Biotechnology industry distribution chart, Septerna ranks #827 out of 1228 companies for PB Ratio. This places Septerna in the lower half of its industry. The industry median PB Ratio is 2.91. Septerna's value of 4.61 is 58.7% above this benchmark. Historically, Septerna's own PB Ratio has ranged from 0.61 to 4.82 over the past decade. While the company's 10-year median is 2.50 vs. the industry median of 2.91, Septerna has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Septerna's current PB Ratio of 4.61 is 58.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Septerna and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Septerna's current PB Ratio is 4.61, which is 84% above median its own 10-year median of 2.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Septerna stock overvalued right now?
Septerna (SEPN) has a current PB Ratio of 4.61. The current PB Ratio is 4.61, which is 84% above median its 10-year median of 2.50 and 58.7% above the Biotechnology industry median of 2.91. Septerna's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Septerna (SEPN), the current PB Ratio is 4.61 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
12GF Score
Get the complete analysis for SEPN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SEPN has been successfully added to your 
